KalVista Pharmaceuticals(KALV) - 2026 Q2 - Quarterly Results

Exhibit 99.1 KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results US launch of EKTERLY® gaining strong momentum with $13.7 million in net product revenue for the third quarter 937 patient start forms received through October, reflecting rapid adoption as first and only oral on-demand treatment for hereditary angioedema (HAE) $309M in cash expected to fund the Company through profitability Management to host conference call Tuesday, November 11th at 8:30 a.m. ET FR ...